147 related articles for article (PubMed ID: 21821631)
1. Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate.
Bala Y; Farlay D; Chapurlat RD; Boivin G
Eur J Endocrinol; 2011 Oct; 165(4):647-55. PubMed ID: 21821631
[TBL] [Abstract][Full Text] [Related]
2. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization.
Bala Y; Depalle B; Farlay D; Douillard T; Meille S; Follet H; Chapurlat R; Chevalier J; Boivin G
J Bone Miner Res; 2012 Apr; 27(4):825-34. PubMed ID: 22189833
[TBL] [Abstract][Full Text] [Related]
3. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
[TBL] [Abstract][Full Text] [Related]
4. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
Roschger P; Lombardi A; Misof BM; Maier G; Fratzl-Zelman N; Fratzl P; Klaushofer K
J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
[TBL] [Abstract][Full Text] [Related]
5. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
Bone HG; Downs RW; Tucci JR; Harris ST; Weinstein RS; Licata AA; McClung MR; Kimmel DB; Gertz BJ; Hale E; Polvino WJ
J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.
Hassler N; Gamsjaeger S; Hofstetter B; Brozek W; Klaushofer K; Paschalis EP
Osteoporos Int; 2015 Jan; 26(1):339-52. PubMed ID: 25315260
[TBL] [Abstract][Full Text] [Related]
7. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
Hofstetter B; Gamsjaeger S; Varga F; Dobnig H; Stepan JJ; Petto H; Pavo I; Klaushofer K; Paschalis EP
Osteoporos Int; 2014 Dec; 25(12):2709-19. PubMed ID: 25037600
[TBL] [Abstract][Full Text] [Related]
8. Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces.
Hofstetter B; Gamsjaeger S; Phipps RJ; Recker RR; Ebetino FH; Klaushofer K; Paschalis EP
J Bone Miner Res; 2012 May; 27(5):995-1003. PubMed ID: 22336962
[TBL] [Abstract][Full Text] [Related]
9. Insights into the bisphosphonate holiday: a preliminary FTIRI study.
Boskey AL; Spevak L; Ma Y; Wang H; Bauer DC; Black DM; Schwartz AV
Osteoporos Int; 2018 Mar; 29(3):699-705. PubMed ID: 29204959
[TBL] [Abstract][Full Text] [Related]
10. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.
Chapurlat RD; Arlot M; Burt-Pichat B; Chavassieux P; Roux JP; Portero-Muzy N; Delmas PD
J Bone Miner Res; 2007 Oct; 22(10):1502-9. PubMed ID: 17824840
[TBL] [Abstract][Full Text] [Related]
11. Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate.
Chavassieux P; Meunier PJ; Roux JP; Portero-Muzy N; Pierre M; Chapurlat R
J Bone Miner Res; 2014 Mar; 29(3):618-28. PubMed ID: 23959630
[TBL] [Abstract][Full Text] [Related]
12. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.
Boivin GY; Chavassieux PM; Santora AC; Yates J; Meunier PJ
Bone; 2000 Nov; 27(5):687-94. PubMed ID: 11062357
[TBL] [Abstract][Full Text] [Related]
13. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
Dalle Carbonare L; Arlot ME; Chavassieux PM; Roux JP; Portero NR; Meunier PJ
J Bone Miner Res; 2001 Jan; 16(1):97-103. PubMed ID: 11149495
[TBL] [Abstract][Full Text] [Related]
14. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
15. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
Olmos JM; Hernández JL; Llorca J; Nan D; Valero C; González-Macías J
J Clin Endocrinol Metab; 2012 Dec; 97(12):4491-7. PubMed ID: 23043189
[TBL] [Abstract][Full Text] [Related]
16. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
Felsenberg D; Bock O; Börst H; Armbrecht G; Beller G; Degner C; Stephan-Oelkers M; Schacht E; Mazor Z; Hashimoto J; Roth HJ; Martus P; Runge M
J Musculoskelet Neuronal Interact; 2011 Mar; 11(1):34-45. PubMed ID: 21364273
[TBL] [Abstract][Full Text] [Related]
17. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
[TBL] [Abstract][Full Text] [Related]
18. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment bone turnover does not influence the level of the response to alendronate in postmenopausal osteoporosis at the bone tissue level.
Chavassieux P; Roux JP; Chapurlat R
Osteoporos Int; 2024 Apr; 35(4):653-658. PubMed ID: 38129674
[TBL] [Abstract][Full Text] [Related]
20. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
